Cargando…

Familial history and prevalence of BRCA1, BRCA2 and TP53 pathogenic variants in HBOC Brazilian patients from a public healthcare service

Several studies have demonstrated the cost-effectiveness of genetic testing for surveillance and treatment of carriers of germline pathogenic variants associated with hereditary breast/ovarian cancer syndrome (HBOC). In Brazil, seventy percent of the population is assisted by the public Unified Heal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matta, Bruna Palma, Gomes, Renan, Mattos, Daniel, Olicio, Renata, Nascimento, Caroline Macedo, Ferreira, Gerson Moura, Brant, Ayslan Castro, Boroni, Mariana, Furtado, Carolina, Lima, Valdirene, Moreira, Miguel Ângelo Martins, dos Santos, Anna Cláudia Evangelista
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633799/ https://www.ncbi.nlm.nih.gov/pubmed/36329109 http://dx.doi.org/10.1038/s41598-022-23012-3

Ejemplares similares

Germline mutations in BRCA1, BRCA2, CHEK2 and TP53 in patients at high-risk for HBOC: characterizing a Northeast Brazilian Population
por: Felix, Gabriela ES, et al.
Publicado: (2014)

Somatic BRCA Mutation in a Cholangiocarcinoma Patient for HBOC Syndrome Detection
por: Paradiso, Angelo Virgilio, et al.
Publicado: (2020)

Mutation screening of BRCA1, BRCA2 and CHEK2*1100delC in Slovak HBOC families
por: Cierniková, S, et al.
Publicado: (2005)

Characteristics of BRCA1/2 pathogenic germline mutations in chinese NSCLC patients and a comparison with HBOC
por: Xu, Zheyuan, et al.
Publicado: (2021)

BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
por: Alemar, Bárbara, et al.
Publicado: (2017)

Correction: BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
por: Alemar, Bárbara, et al.
Publicado: (2018)

BRCA1 and BRCA2 rearrangements in Brazilian individuals with Hereditary Breast and Ovarian Cancer Syndrome
por: Ewald, Ingrid Petroni, et al.
Publicado: (2016)

brca2 and tp53 Collaborate in Tumorigenesis in Zebrafish
por: Shive, Heather R., et al.
Publicado: (2014)

Screening of BRCA1/2 genes mutations and copy number variations in patients with high risk for hereditary breast and ovarian cancer syndrome (HBOC)
por: El Ansari, Fatima Zahra, et al.
Publicado: (2020)

KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer
por: Cicenas, Jonas, et al.
Publicado: (2017)

HBOC syndrome with an uncharacterized variant in the BRCA1 gene in a patient diagnosed with endometrial cancer after surgery for bilateral breast cancer: A case report
por: Mabuchi, Yasushi, et al.
Publicado: (2022)

Surgery for BRCA, TP53 and PALB2: a literature review
por: Song, Chin-Vern, et al.
Publicado: (2018)

BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2
por: Cline, Melissa S., et al.
Publicado: (2018)

Comprehensive Analysis of BRCA1, BRCA2 and TP53 Germline Mutation and Tumor Characterization: A Portrait of Early-Onset Breast Cancer in Brazil
por: Carraro, Dirce Maria, et al.
Publicado: (2013)

Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients
por: Lee, Daphne SC, et al.
Publicado: (2012)

The germline mutational landscape of BRCA1 and BRCA2 in Brazil
por: Palmero, Edenir Inêz, et al.
Publicado: (2018)

The spectrum of BRCA1 and BRCA2 alleles in Latin America and the Caribbean: a clinical perspective
por: Dutil, Julie, et al.
Publicado: (2015)

Haplotypic characterization of BRCA1 c.5266dupC, the prevailing mutation in Brazilian hereditary breast/ovarian cancer
por: Gomes, Renan, et al.
Publicado: (2020)

Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent
por: Cavallone, Luca, et al.
Publicado: (2008)

Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk
por: Baynes, Caroline, et al.
Publicado: (2007)

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
por: Maxwell, Kara N., et al.
Publicado: (2017)

Prediction of the functional impact of missense variants in BRCA1 and BRCA2 with BRCA-ML
por: Hart, Steven N., et al.
Publicado: (2020)

Prevalence of hereditary breast and ovarian cancer (HBOC) predisposition gene mutations among 882 HBOC high‐risk Chinese individuals
por: Shao, Di, et al.
Publicado: (2019)

The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Sinilnikova, O M, et al.
Publicado: (2009)

Epistatic Relationships in the BRCA1-BRCA2 Pathway
por: Scully, Ralph
Publicado: (2011)

A model of the BRCA1/BRCA2 network
por: Pujana, MA, et al.
Publicado: (2005)

Molecular Trajectory of BRCA1 and BRCA2 Mutations
por: Hatano, Yuichiro, et al.
Publicado: (2020)

Screening for germline BRCA1, BRCA2, TP53 and CHEK2 mutations in families at-risk for hereditary breast cancer identified in a population-based study from Southern Brazil
por: Palmero, Edenir Inêz, et al.
Publicado: (2016)

Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status
por: Evans, D G R, et al.
Publicado: (2010)

BRCA1 and TP53 codeficiency causes a PARP inhibitor–sensitive erythroproliferative neoplasm
por: Lopez-Perez, Gerardo, et al.
Publicado: (2022)

Combined Tumor-Based BRCA1/2 and TP53 Mutation Testing in Ovarian Cancer
por: Borcoman, Edith, et al.
Publicado: (2023)

Editorial: HBOC and high-risk screening: up-to-date
por: Kataoka, Masako
Publicado: (2021)

Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry
por: Fernandes, Gabriela C., et al.
Publicado: (2016)

BRCA1 and BRCA2 mutations in Scotland and Northern Ireland
Publicado: (2003)

Clinical significance of large rearrangements in BRCA1 and BRCA2
por: Judkins, Thaddeus, et al.
Publicado: (2012)

Autoimmune response to PARP and BRCA1/BRCA2 in cancer
por: Zhu, Qing, et al.
Publicado: (2015)

BRCA1 and BRCA2 Tumor Suppressor Function in Meiosis
por: Li, Qianyan, et al.
Publicado: (2021)

Prediction of carrying a BRCA1 or BRCA2 mutation
por: Lee, Kyung-Hun
Publicado: (2023)

BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity
por: Tacconi, Eliana MC, et al.
Publicado: (2017)

An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA)
por: Chenevix-Trench, Georgia, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_4qvcnae7nf093ntu0mbcaahu5g